Myovant punished for success
A phase III win for the company’s uterine fibroids candidate fails to calm investor concerns about an expensive launch and a rival with deeper pockets.
Roxadustat safety analysis provokes more questions than answers
Fibrogen tumbles on a confusing safety update for its most advanced project.
Astra makes machine learning bet with Benevolent AI deal
Astrazeneca has made another push into artificial intelligence, but admits that it will be some time before it knows whether the technology has helped its drug discovery…
Go or no go? Novartis, Sanofi and Regeneron await US verdicts
May looks to be a fairly quiet month for US drug approvals, though Novartis's gene therapy should make headlines.
Boston and Coloplast sink on mesh mess
Transvaginal mesh implants are banned in the US, but remain a possibility in Europe.
ISN 2019 – Kidney benefit could help Invokana compete again
Johnson & Johnson’s Invokana has fallen behind SGLT2 rivals over amputation fears, but success in the Credence renal trial, profiled at the International Society of…
Short the launch starts early for Urovant
For Urovant, beating placebo in a pivotal trial of vibegron was the easy part.
First big test approaches for Urovant
Six months after floating, Urovant is gearing up to release pivotal data on its most advanced overactive bladder project.
Reata gives Abbvie something else to think about
As the final cohort in the Phoenix trial reads out positively for bardoxolone the stage is set for pivotal results and a decision by Abbvie.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.